RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ADMA Biologics Stock

ADMA Biologics Revenue 2024

ADMA Biologics Revenue

413.87 M USD

Ticker

ADMA

ISIN

US0008991046

WKN

A12FAG

In 2024, ADMA Biologics's sales reached 413.87 M USD, a 60.28% difference from the 258.22 M USD sales recorded in the previous year.

The ADMA Biologics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e591.2915,40
2028e554.8316,41
2027e529.0717,21
2026e554.5716,42
2025e470.4419,35
2024e413.8722,00
2023258.2235,26
2022154.122,91
202180.91,48
202042.2-45,26
201929.3-34,81
201817-148,24
201722.8-28,07
201610.740,19
20157.240,28
20145.937,29
20133.132,26
20121.136,36
20110.8-175,00
2010--

ADMA Biologics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ADMA Biologics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ADMA Biologics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ADMA Biologics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ADMA Biologics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ADMA Biologics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ADMA Biologics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ADMA Biologics’s growth potential.

ADMA Biologics Revenue, EBIT and net profit per share

DateADMA Biologics RevenueADMA Biologics EBITADMA Biologics Net Income
2029e591.29 M undefined0 undefined164.04 M undefined
2028e554.83 M undefined213.95 M undefined154.53 M undefined
2027e529.07 M undefined205.53 M undefined167.61 M undefined
2026e554.57 M undefined187.58 M undefined171.17 M undefined
2025e470.44 M undefined152.34 M undefined158.5 M undefined
2024e413.87 M undefined102.7 M undefined116.49 M undefined
2023258.22 M undefined23.73 M undefined-28.24 M undefined
2022154.1 M undefined-39.3 M undefined-65.9 M undefined
202180.9 M undefined-58.4 M undefined-71.6 M undefined
202042.2 M undefined-64.9 M undefined-75.7 M undefined
201929.3 M undefined-41.4 M undefined-48.3 M undefined
201817 M undefined-60.3 M undefined-65.7 M undefined
201722.8 M undefined-38.4 M undefined-43.8 M undefined
201610.7 M undefined-17.3 M undefined-19.5 M undefined
20157.2 M undefined-15.5 M undefined-18 M undefined
20145.9 M undefined-16 M undefined-16.8 M undefined
20133.1 M undefined-15 M undefined-15.5 M undefined
20121.1 M undefined-7.9 M undefined-7.3 M undefined
2011800,000 undefined-4.6 M undefined-5.9 M undefined
20100 undefined-5.5 M undefined-5.9 M undefined

ADMA Biologics stock margins

The ADMA Biologics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ADMA Biologics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ADMA Biologics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ADMA Biologics's sales revenue. A higher gross margin percentage indicates that the ADMA Biologics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ADMA Biologics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ADMA Biologics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ADMA Biologics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ADMA Biologics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ADMA Biologics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ADMA Biologics Margin History

ADMA Biologics Gross marginADMA Biologics Profit marginADMA Biologics EBIT marginADMA Biologics Profit margin
2029e35.26 %0 %27.74 %
2028e35.26 %38.56 %27.85 %
2027e35.26 %38.85 %31.68 %
2026e35.26 %33.82 %30.87 %
2025e35.26 %32.38 %33.69 %
2024e35.26 %24.81 %28.15 %
202335.26 %9.19 %-10.94 %
202222.91 %-25.5 %-42.76 %
20211.48 %-72.19 %-88.5 %
2020-45.26 %-153.79 %-179.38 %
2019-34.81 %-141.3 %-164.85 %
2018-148.24 %-354.71 %-386.47 %
2017-28.07 %-168.42 %-192.11 %
201640.19 %-161.68 %-182.24 %
201540.28 %-215.28 %-250 %
201437.29 %-271.19 %-284.75 %
201332.26 %-483.87 %-500 %
201236.36 %-718.18 %-663.64 %
2011-175 %-575 %-737.5 %
201035.26 %0 %0 %

ADMA Biologics Aktienanalyse

What does ADMA Biologics do?

ADMA Biologics is a leading company in the development and manufacturing of biological therapies for the treatment of serious diseases. The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics' business model is based on the development and manufacturing of specialized biological therapies tailored to the needs of patients with rare diseases and severe infections. It specializes in the development of plasma-based therapies to treat patients with immune deficiency and autoimmune diseases, hemophilia, and severe blood loss due to trauma or surgery. ADMA Biologics' products include intravenously administered immune globulin (IVIG) called BIVIGAM, approved for intravenous infusion in patients with primary immune deficiency or other immune disorders. CyclASol, an eye drop for patients with the eye inflammation Keratoconjunctivitis Sicca, is also a product developed by ADMA Biologics. Additionally, ADMA Biologics is currently expanding its product portfolio through the development of PDIG, a product in phase III clinical trial for the treatment of secondary immune deficiencies. The company has long-standing partnerships with other companies and organizations in the industry to combine its resources and expertise in the development and marketing of innovative therapies. ADMA Biologics also operates its own plasma collection center to ensure the supply of plasma for its therapies. In terms of its divisions, ADMA Biologics currently focuses on the USA, where the company offers its products through a dedicated sales team. Additionally, ADMA Biologics aims to expand its presence worldwide by introducing its products into new regions and markets. The company has achieved important regulatory milestones in Europe and other parts of the world, including the approval of BIVIGAM's sale in Korea and the Industrial Ministry Jubilee Memorial for BIVIGAM's introduction in Japan. ADMA Biologics' history began in 2004 when the company specialized in the development and manufacturing of plasma-based therapies for patients with rare diseases. In 2009, the company received its first FDA approval for ASCENIV, an immune globulin product for the treatment of immune deficiency disorders. In 2011, ADMA Biologics acquired a plasma collection center to expand its resources and capabilities and ensure an independent supply chain for plasma. Since then, the company has gained importance in the industry through the development and introduction of innovative products and therapies. In 2018, ADMA Biologics established a subsidiary in Germany to support the company's expansion into the European continent. In the same year, the company also obtained FDA approval in the United States for BIVIGAM, the first IVIG product manufactured from human plasma in the country. Overall, ADMA Biologics has a strong brand presence in the industry and is successfully expanding its portfolio of plasma-based therapies. The company has established strong partnerships with organizations in the industry to jointly develop and bring innovative solutions to a wide range of diseases. ADMA Biologics has a very positive future outlook and is expected to play a significant role in the field of biological therapies by continuing to develop and bring innovative therapies to the market. ADMA Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding ADMA Biologics's Sales Figures

The sales figures of ADMA Biologics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing ADMA Biologics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize ADMA Biologics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in ADMA Biologics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about ADMA Biologics stock

How much revenue did ADMA Biologics generate this year?

ADMA Biologics has achieved a revenue of 413.87 M USD this year.

How much was the turnover of the company ADMA Biologics compared to the previous year?

The revenue of ADMA Biologics has increased by 60.28% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of ADMA Biologics?

The revenue of ADMA Biologics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of ADMA Biologics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of ADMA Biologics so important for investors?

The revenue of ADMA Biologics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does ADMA Biologics pay?

Over the past 12 months, ADMA Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADMA Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of ADMA Biologics?

The current dividend yield of ADMA Biologics is .

When does ADMA Biologics pay dividends?

ADMA Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ADMA Biologics?

ADMA Biologics paid dividends every year for the past 0 years.

What is the dividend of ADMA Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ADMA Biologics located?

ADMA Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ADMA Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ADMA Biologics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did ADMA Biologics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of ADMA Biologics in the year 2023?

In the year 2023, ADMA Biologics distributed 0 USD as dividends.

In which currency does ADMA Biologics pay out the dividend?

The dividends of ADMA Biologics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ADMA Biologics

Our stock analysis for ADMA Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ADMA Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.